Usart M, Kimmerlin Q, Stetka J, Stoll C, Rai S, Almeida Fonseca T
Leukemia. 2025; .
PMID: 40069287
DOI: 10.1038/s41375-025-02550-5.
Handa S, Schaniel C, Tripodi J, Ahire D, Mia M, Klingborg S
Leukemia. 2024; 39(3):663-674.
PMID: 39715853
PMC: 11879852.
DOI: 10.1038/s41375-024-02496-0.
Rejaibi R, Guille A, Manai M, Adelaide J, Agavnian E, Jelassi A
Sci Rep. 2024; 14(1):28573.
PMID: 39562613
PMC: 11577113.
DOI: 10.1038/s41598-024-80030-z.
Ueda K, Ikeda K
Fukushima J Med Sci. 2023; 70(1):11-24.
PMID: 37952978
PMC: 10867434.
DOI: 10.5387/fms.2023-17.
Minervini A, Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F
Cancers (Basel). 2020; 12(6).
PMID: 32503270
PMC: 7353061.
DOI: 10.3390/cancers12061456.
Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.
Cervera N, Lhoumeau A, Adelaide J, Guille A, Murati A, Mozziconacci M
Haematologica. 2019; 105(7):e340-e342.
PMID: 31601691
PMC: 7327663.
DOI: 10.3324/haematol.2019.231142.
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
Marcellino B, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J
Blood Adv. 2018; 2(24):3581-3589.
PMID: 30563882
PMC: 6306879.
DOI: 10.1182/bloodadvances.2018024018.
miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression.
Epis M, Giles K, Beveridge D, Richardson K, Candy P, Stuart L
Oncotarget. 2017; 8(33):55116-55134.
PMID: 28903407
PMC: 5589646.
DOI: 10.18632/oncotarget.18664.
The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer.
Naudin C, Chevalier C, Roche S
Oncotarget. 2016; 7(10):11033-55.
PMID: 26788993
PMC: 4905456.
DOI: 10.18632/oncotarget.6929.
Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
Benton C, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J
Leuk Res. 2015; 39(4):419-23.
PMID: 25687833
PMC: 4847531.
DOI: 10.1016/j.leukres.2015.01.012.
SOCS proteins in regulation of receptor tyrosine kinase signaling.
Kazi J, Kabir N, Flores-Morales A, Ronnstrand L
Cell Mol Life Sci. 2014; 71(17):3297-310.
PMID: 24705897
PMC: 11113172.
DOI: 10.1007/s00018-014-1619-y.
Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms.
Brecqueville M, Adelaide J, Bertucci F, Finetti P, Chaffanet M, Birnbaum D
Cell Cycle. 2012; 11(16):3141-2.
PMID: 22825250
PMC: 3442924.
DOI: 10.4161/cc.21114.
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.
Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E
EMBO Mol Med. 2011; 3(3):153-66.
PMID: 21328542
PMC: 3395112.
DOI: 10.1002/emmm.201100121.
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.
Gelsi-Boyer V, Trouplin V, Adelaide J, Aceto N, Remy V, Pinson S
BMC Cancer. 2008; 8:299.
PMID: 18925961
PMC: 2588460.
DOI: 10.1186/1471-2407-8-299.
HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma.
Hristov A, Cope L, Reyes M, Singh M, Iacobuzio-Donahue C, Maitra A
Mod Pathol. 2008; 22(1):43-9.
PMID: 18843278
PMC: 2769577.
DOI: 10.1038/modpathol.2008.140.
Characterization of apparently balanced chromosomal rearrangements from the developmental genome anatomy project.
Higgins A, Alkuraya F, Bosco A, Brown K, Bruns G, Donovan D
Am J Hum Genet. 2008; 82(3):712-22.
PMID: 18319076
PMC: 2427206.
DOI: 10.1016/j.ajhg.2008.01.011.